## Empiric Therapy for CAP: First-Line vs. Suboptimal Agents **Key Point:** Azithromycin monotherapy is NOT recommended as first-line empiric therapy for CAP, especially in a patient with comorbidity (COPD). It is inadequate against *Streptococcus pneumoniae* and atypical organisms when used alone, and has poor lung penetration for some pathogens. ### Recommended First-Line Regimens for CAP (Indian Guidelines) | Regimen | Indication | Notes | |---------|-----------|-------| | Amoxicillin-clavulanate (oral or IV) | Mild-to-moderate CAP, outpatient | Good for *S. pneumoniae*, *H. influenzae* | | Fluoroquinolone (levofloxacin/moxifloxacin) | Mild-to-moderate or severe CAP | Covers atypicals; respiratory fluoroquinolone | | Beta-lactam + macrolide (ceftriaxone + azithromycin) | Moderate-to-severe CAP, hospitalized | Covers *S. pneumoniae*, atypicals, *H. influenzae* | | Azithromycin monotherapy | NOT recommended | Inadequate coverage; resistance emerging | **High-Yield:** Azithromycin should NEVER be used as monotherapy for CAP in India. It is reserved as part of combination therapy (e.g., with a beta-lactam) or for atypical pathogen coverage only. **Clinical Pearl:** In a patient with COPD and CAP, broader coverage is needed because of risk of *H. influenzae* and gram-negative organisms; monotherapy with a macrolide is insufficient. **Warning:** Do not confuse azithromycin's role in atypical pneumonia (where it is useful as part of combination therapy) with its use as monotherapy (which is inadequate). [cite:Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.